Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
RESEARCH TOOLSreports
INO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.74 - $14.75
Previous CloseN/A
Volume1.36M
Average Volume (3M)966.04K
Market Cap
$79.06M
Enterprise Value$90.29M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Mar 04, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding36,099,990
10 Day Avg. Volume713,827
30 Day Avg. Volume966,036
Standard Deviation0.29
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)281.00
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.80
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$10.50Price Target Upside372.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTop-line results point to sustained and deepening responses, which are viewed as encouraging for eventual patient and payer uptake.
Efficacy And SafetyNo treatment-emergent serious adverse events were identified in the trial, suggesting a favorable safety profile for INO-3107.
Regulatory ProgressINO-3107 has been granted Breakthrough Therapy designation, which could qualify it for priority review.
Bears Say
Capital NeedsThe company may need to raise additional capital within the next 12 months.
Manufacturing IssuesManagement expects to resolve the single-use array manufacturing issue by February 2025.
Stock Rating And Price TargetAnalyst reiterates a Neutral rating while adjusting the 12-month price target to $3 from $5 per share.
---
Ownership Overview
0.61% Insiders
6.77% Mutual Funds
16.02% Other Institutional Investors
69.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.74 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $79.06M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 11 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 14, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.15 by $0.26.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.84.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 36,099,990 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.15. Following the earnings report the stock price went down -10.692%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
---
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (372.97% Upside)
$10.50 (372.97% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.00%
12-Months-Change
Fundamentals
Return on Equity
-106.64%
Trailing 12-Months
Asset Growth
-44.56%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
INO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant progress on the lead product candidate INO-3107 and financial discipline, though challenges remain with a manufacturing issue and cash runway concerns.Read More>---
INO Stock 12 Month Forecast
Average Price Target
$10.50
▲(372.97% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-67.93%
reiterated a buy rating 3 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -67.93% per trade.
---